Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment and ensuring patient safety.

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They’re Offering Ozempic for $499 a Month.